Toronto - Free Realtime Quote CAD

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

5.39
+0.07
+(1.32%)
As of 1:33:22 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
27,003.41
27,003.41
27,847.23
17,617.45
14,648.93
Operating Income
-27,003.41
-27,003.41
-27,847.23
-17,617.45
-14,648.93
Net Non Operating Interest Income Expense
556.37
556.37
-307.20
-551.06
-965.44
Other Income Expense
704.36
704.36
-775.15
-822.26
-2,714.40
Pretax Income
-25,742.69
-25,742.69
-28,929.58
-18,990.76
-18,328.77
Tax Provision
1.80
1.80
36.42
0
--
Net Income Common Stockholders
-25,502.54
-25,502.54
-28,220.80
-18,489.63
-18,030.78
Diluted NI Available to Com Stockholders
-25,502.54
-25,502.54
-28,220.80
-18,489.63
-18,030.78
Basic EPS
-0.93
-0.76
-1.17
-0.96
-1.47
Diluted EPS
-0.93
-0.76
-1.17
-0.96
-1.47
Basic Average Shares
31,847.41
33,930.58
24,146.62
19,285.45
12,405.84
Diluted Average Shares
31,847.41
33,930.58
24,146.62
19,285.45
12,405.84
Total Expenses
27,003.41
27,003.41
27,847.23
17,617.45
14,648.93
Net Income from Continuing & Discontinued Operation
-25,502.54
-25,502.54
-28,220.80
-18,489.63
-18,030.78
Normalized Income
-26,101.24
-26,101.24
-27,755.71
-17,667.37
-17,089.28
Interest Income
1,159.94
1,159.94
862.97
431.80
51.55
Interest Expense
603.57
603.57
1,170.17
982.86
1,016.99
Net Interest Income
556.37
556.37
-307.20
-551.06
-965.44
EBIT
-25,139.11
-25,139.11
-27,759.41
-18,007.91
-17,311.78
EBITDA
-24,967.39
-24,967.39
-27,603.88
-17,860.01
-17,224.31
Reconciled Depreciation
171.72
171.72
155.53
147.89
87.47
Net Income from Continuing Operation Net Minority Interest
-25,502.54
-25,502.54
-28,220.80
-18,489.63
-18,030.78
Total Unusual Items Excluding Goodwill
704.36
704.36
-775.15
-822.26
-941.50
Total Unusual Items
704.36
704.36
-775.15
-822.26
-941.50
Normalized EBITDA
-25,671.75
-25,671.75
-26,828.73
-17,037.76
-16,282.80
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
105.65
105.65
-310.06
0
0
12/31/2021 - 3/9/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MDNA.TO Medicenna Therapeutics Corp.
1.0700
+7.00%
 
MSCL.TO Satellos Bioscience Inc.
0.6500
0.00%
 
FRX.TO Fennec Pharmaceuticals Inc.
9.04
0.00%
 
MSCLF Satellos Bioscience Inc.
0.4820
0.00%
 
ENGN enGene Holdings Inc.
3.0700
-9.50%
 
ENGNW enGene Holdings Inc.
0.7300
-2.67%
 
RKV.V Rakovina Therapeutics Inc.
0.0450
0.00%
 
XENE Xenon Pharmaceuticals Inc.
35.09
-1.28%
 
NYMXF Nymox Pharmaceutical Corporation
0.0902
-9.80%
 
ONCO.CN Onco-Innova
1.5000
-0.66%